Skip to main content
Premium Trial:

Request an Annual Quote

Lentigen to Use NIH Grants with NCI, USC in Lentiviral Vector Therapy Studies

NEW YORK (GenomeWeb News) – Lentigen said yesterday it will use four grants from the National Institutes of Health to develop novel treatments for several diseases.
Lentigen, a lentiviral vector technology developer, said it will use the four small business innovation research grants to fund studies in melanoma and hepatitis C virus in collaboration with Michael Nishimura of the University of South Carolina, and studies of Epstein-Barr virus-related diseases and chronic lymphocytic leukemia in collaboration with Adrian Wiestner at the National Cancer Institute.
Baltimore-based Lentigen will work with these collaborators to develop lentiviral vectors, which are used to deliver genes or gene silencing sequences into cells and target specific diseases.
The company did not release the dollar value of the SBIR grants.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.